These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 25720504)
1. TAPBPR: a new player in the MHC class I presentation pathway. Hermann C; Trowsdale J; Boyle LH Tissue Antigens; 2015 Mar; 85(3):155-66. PubMed ID: 25720504 [TBL] [Abstract][Full Text] [Related]
8. The role of MHC I protein dynamics in tapasin and TAPBPR-assisted immunopeptidome editing. van Hateren A; Elliott T Curr Opin Immunol; 2021 Jun; 70():138-143. PubMed ID: 34265495 [TBL] [Abstract][Full Text] [Related]
9. The binding of TAPBPR and Tapasin to MHC class I is mutually exclusive. Hermann C; Strittmatter LM; Deane JE; Boyle LH J Immunol; 2013 Dec; 191(11):5743-50. PubMed ID: 24163410 [TBL] [Abstract][Full Text] [Related]
10. Preferential interaction of MHC class I with TAPBPR in the absence of glycosylation. Neerincx A; Boyle LH Mol Immunol; 2019 Sep; 113():58-66. PubMed ID: 30077416 [TBL] [Abstract][Full Text] [Related]
11. TAPBPR mediates peptide dissociation from MHC class I using a leucine lever. Ilca FT; Neerincx A; Hermann C; Marcu A; Stevanović S; Deane JE; Boyle LH Elife; 2018 Nov; 7():. PubMed ID: 30484775 [TBL] [Abstract][Full Text] [Related]
12. TAPBPR isoforms exhibit altered association with MHC class I. Porter KM; Hermann C; Traherne JA; Boyle LH Immunology; 2014 Jun; 142(2):289-99. PubMed ID: 24444341 [TBL] [Abstract][Full Text] [Related]
13. TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst. Hermann C; van Hateren A; Trautwein N; Neerincx A; Duriez PJ; Stevanović S; Trowsdale J; Deane JE; Elliott T; Boyle LH Elife; 2015 Oct; 4():. PubMed ID: 26439010 [TBL] [Abstract][Full Text] [Related]
14. Structural and dynamic studies of TAPBPR and Tapasin reveal the mechanism of peptide loading of MHC-I molecules. Margulies DH; Jiang J; Natarajan K Curr Opin Immunol; 2020 Jun; 64():71-79. PubMed ID: 32402827 [TBL] [Abstract][Full Text] [Related]
15. TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap. McShan AC; Devlin CA; Morozov GI; Overall SA; Moschidi D; Akella N; Procko E; Sgourakis NG Nat Commun; 2021 May; 12(1):3174. PubMed ID: 34039964 [TBL] [Abstract][Full Text] [Related]
16. A loop structure allows TAPBPR to exert its dual function as MHC I chaperone and peptide editor. Sagert L; Hennig F; Thomas C; Tampé R Elife; 2020 Mar; 9():. PubMed ID: 32167472 [TBL] [Abstract][Full Text] [Related]
17. Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR. Ilca FT; Drexhage LZ; Brewin G; Peacock S; Boyle LH Cell Rep; 2019 Nov; 29(6):1621-1632.e3. PubMed ID: 31693900 [TBL] [Abstract][Full Text] [Related]
18. MHC I chaperone complexes shaping immunity. Thomas C; Tampé R Curr Opin Immunol; 2019 Jun; 58():9-15. PubMed ID: 30771631 [TBL] [Abstract][Full Text] [Related]
19. Molecular architecture of the MHC I peptide-loading complex: one tapasin molecule is essential and sufficient for antigen processing. Hulpke S; Baldauf C; Tampé R FASEB J; 2012 Dec; 26(12):5071-80. PubMed ID: 22923333 [TBL] [Abstract][Full Text] [Related]
20. Tapasin: an ER chaperone that controls MHC class I assembly with peptide. Grandea AG; Van Kaer L Trends Immunol; 2001 Apr; 22(4):194-9. PubMed ID: 11274924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]